Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Apogee Therapeutics

Apogee Therapeutics Reaches 80-Plus Relative Strength Rating Benchmark

Apogee Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 73 to 84.

Investors Business Daily

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out

Shares of Apogee Therapeutics have gained 34% over the past two days as the small biotech looks to take on Regeneron and Sanofi.

Investors Business Daily

Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.

Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.

Apogee Therapeutics shares crumbled Monday despite promising results for what could become a quarterly or twice-yearly shot to control eczema.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket

Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) rose sharply in today's pre-market trading after the company disclosed positive 16-week data from Phase 2 APEX clinical trial of APG777, its potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis.

Apogee Therapeutics Shows Rising Relative Price Performance; Still Shy Of Key Benchmark

A Relative Strength Rating upgrade for Apogee Therapeutics shows improving technical performance. Will it continue?

Investors Business Daily

Apogee Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Benchmark

A Relative Strength Rating upgrade for Apogee Therapeutics shows improving technical performance.

Investors Business Daily

Apogee Therapeutics Trying To Close In On Key Technical Measure

Apogee Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Stocks Showing Rising Market Leadership: Apogee Therapeutics Earns 83 RS Rating

Stocks Showing Rising Market Leadership: Apogee Therapeutics Earns 83 RS Rating

A Relative Strength Rating upgrade for Apogee Therapeutics shows improving technical performance.

Investors Business Daily

Stocks Showing Rising Market Leadership: Apogee Therapeutics Earns 86 RS Rating

Stocks Showing Rising Market Leadership: Apogee Therapeutics Earns 86 RS Rating

Apogee Therapeutics sees its Relative Strength Rating hit the 80-plus level.

Investors Business Daily

Stocks To Watch: Apogee Therapeutics Sees RS Rating Jump To 91

Stocks To Watch: Apogee Therapeutics Sees RS Rating Jump To 91

A Relative Strength Rating upgrade for Apogee Therapeutics shows improving technical performance.

Investors Business Daily

2 Russell 2000 Stocks With More Than 29% Upside Potential to Grab Now

2 Russell 2000 Stocks With More Than 29% Upside Potential to Grab Now

Wall Street rates both of these outperforming small-cap stocks a “strong buy," with 29% or more upside expected over the next year.

5 Russell 2000 Stocks Outperforming the 'Magnificent Seven' in 2024

5 Russell 2000 Stocks Outperforming the 'Magnificent Seven' in 2024

The "Magnificent Seven" have lost some momentum in 2024, just as small-caps are starting to come on strong. Here's a closer look at five Russell 2000 stocks that are crushing the performance of their mega-cap peers so far this year.

Organisations

Viking Therapeutics

Apogee Therapeutics

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play